NCT05515029View on ClinicalTrials.gov

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 23, 2022

Primary Completion Date

August 15, 2024

Study Completion Date

October 16, 2026

Conditions
Acute Lymphoblastic LeukemiaMyeloblastic LeukemiaBiphenotypic Acute LeukemiaMalignant LymphomaMyelodysplastic SyndromesJuvenile Myelomonocytic Leukemia
Interventions
COMBINATION_PRODUCT

GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor

Cyclophosphamide 100 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +45, +60, +90, +120 Vedolizumab 10 mg/kg/day, max. 300 mg on the days -1, +14, +28

Trial Locations (1)

11198

Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow

All Listed Sponsors
lead

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

OTHER